Dasatinib in Relapsed Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Dasatinib
Related studies linked through entity extraction aliases.
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Gemcitabine and Dasatinib in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone
- Status
- COMPLETED
- Phase
- PHASE2
Treatment of Adult Ph+ LAL With BMS-354825
- Status
- COMPLETED
- Phase
- PHASE2
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
- Status
- COMPLETED
- Phase
- N/A
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
- Status
- TERMINATED
- Phase
- PHASE3
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
- Status
- TERMINATED
- Phase
- PHASE2
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
- Status
- COMPLETED
- Phase
- PHASE1
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
- Status
- COMPLETED
- Phase
- PHASE1